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Neuregulin 1 (NRG1) is a schizophrenia candidate gene 
whose protein product is involved in neuronal migration, 
survival, and synaptic plasticity via production of spe-
cific isoforms. Importantly, NRG1 type III (NRG1 III) 
mRNA is increased in humans inheriting a schizophrenia 
risk haplotype for the NRG1 gene (HapICE), and NRG1 
protein levels can be elevated in schizophrenia. The 
nature by which NRG1 type III overexpression results in 
schizophrenia-like behavior and brain pathology remains 
unclear, therefore we constructed a transgenic mouse with 
Nrg1 III overexpression in forebrain neurons (CamKII 
kinase+). Here, we demonstrate construct validity for 
this mouse model, as juvenile and adult Nrg1 III trans-
genic mice exhibit an overexpression of Nrg1 III mRNA 
and Nrg1 protein in multiple brain regions. Furthermore, 
Nrg1 III transgenic mice have face validity as they exhibit 
schizophrenia-relevant behavioral phenotypes including 
deficits in social preference, impaired fear-associated 
memory, and reduced prepulse inhibition. Additionally, 
microarray assay of hippocampal mRNA uncovered tran-
scriptional alterations downstream of Nrg1 III overex-
pression, including changes in serotonin receptor 2C and 
angiotensin-converting enzyme. Transgenic mice did not 
exhibit other schizophrenia-relevant behaviors including 
hyperactivity, social withdrawal, or an increased vulner-
ability to the effects of MK-801 malate. Our results indi-
cate that this novel Nrg1 III mouse is valid for modeling 
potential pathological mechanisms of some schizophre-
nia-like behaviors, for determining what other neurobio-
logical changes may be downstream of elevated NRG1 III 
levels and for preclinically testing therapeutic strategies 
that may be specifically efficacious in patients with the 
NRG1 (HapICE) risk genotype.
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Introduction
Neuregulin 1 (NRG1) has been associated with the risk of 
developing schizophrenia across multiple ethnic popula-
tions,1–3 but not in all genetic studies (ie, Duan et al,4 for a 
recent review, see Mostaid and colleagues5). Despite this, 
continuing to assess the role of abnormal NRG1 signal-
ing in schizophrenia is warranted due to the heterogene-
ity of NRG1 in schizophrenia6 (which may explain the 
difficulties in detecting association in genetic studies), the 
numerous preclinical studies which illustrate the potency 
by which Nrg1 perturbations induce schizophrenia-like 
phenotypes, the studies of postmortem brain which 
implicated altered Nrg1/ErbB4 levels in the disease5 and 
also a recent meta-analysis of NRG1 in schizophrenia 
which supports that a genetic association may exist in 
some populations.7 The NRG1 gene encodes the NRG1 
protein, which mediates cell survival, synaptic plasticity, 
neuronal migration, and myelination.8,9 Over 30 different 
unique isoforms of NRG1 are categorized into 6 main 
types (types I–VI) depending on the identity of proteins 
in the N-terminus.10,11 The type III isoform (NRG1 III) 
is unique as it contains a cysteine-rich domain in the 
N-terminus and a transmembrane domain and thus, pos-
sesses 2 cleavable transmembrane regions.10,12 NRG1 III is 
also the most highly expressed NRG1 isoform type in the 
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adult human and rodent brain suggesting that it may be 
the most neurobiologically significant and behaviorally 
potent NRG1 type.13
Recently, we identified a putative molecular mech-
anism for increasing genetic risk for schizophrenia 
whereby inheriting more copies of the NRG1 schizophre-
nia risk haplotype (named HapICE) increases the cortical 
expression of NRG1 III mRNA,6 while another study has 
shown that the ratio of NRG1 II mRNA to NRG1 III 
is decreased in schizophrenia.14 This compliments earlier 
studies where elevated levels of brain NRG1 I and IV 
mRNA,14,15 NRG1 protein16 and increased NRG1 sig-
naling in postmortem tissue from schizophrenia patients 
have been observed.17 Together, this evidence suggests 
that a gain of function of NRG1 may serve as a contrib-
uting factor to the pathophysiology of this mental dis-
order although there is debate about which isoform of 
NRG1 contributes most strongly to schizophrenia.14,18
Genetic disruptions that either model decreased or 
increased expression of particular Nrg1 isoforms can confer 
distinct schizophrenia-like behavioral phenotypes. A mouse 
model with a haploinsufficiency for Nrg1 III has impaired 
prepulse inhibition (PPI) and cognitive deficits in delayed 
alternation in the T-maze.19 In gain-of-function Nrg1 mouse 
models, Nrg1 type I overexpression leads to hyperlocomo-
tion, deficits in learned fear to a context (but not to a cue)20,21 
as well as reduced cognitive performance in spatial tasks22 
social interaction, impaired social recognition memory, and 
PPI deficits.21,23 The behavioral impact of expected neurobi-
ological change resulting from inheriting the NRG1 HapICE, 
NRG1 III overexpression, has not yet been behaviorally 
characterized even though an overexpressing Nrg1 III trans-
genic mouse model was created in 2004.24 This Nrg1 III 
mouse is not suited for assessing schizophrenia-like behav-
iors as the neuromuscular junction in these mice is severely 
compromised and exhibits a tremor.25 Thus, we sought to 
construct a mouse that could be validated for both overpro-
duction of brain Nrg1 III and for schizophrenia-like behav-
ioral and brain biological phenotypes.
Materials and Methods
Generation of Transgenic Animals
Briefly, a transgenic mouse with CamKII promoter driven 
Neuregulin 1 type III was generated on a C57BL/6NTac 
background (for details, see supplementary methods).
Test Animals
For our behavioral studies, male heterozygous Neuregulin 
1 type III overexpressing mice (Nrg1 III tg) (n = 10) and 
male wild type (WT) (n = 10) control littermates aged 
28 (±2) weeks were used. For mRNA assays, male Nrg1 
III tg mice and WT aged 28 days and 39.5 (±2.5) weeks 
were used, while mice aged 39.5 (±2.5 weeks) were used 
for protein western blotting. Research and animal care 
procedures were approved by the University of New 
South Wales Animal Care and Ethics Committee and 
were in accordance with the Australian Code of Practice 
for the Care and Use of Animals for Scientific Purposes 
(ACEC#14/49A) (refer to supplementary methods).
Molecular Confirmation of Nrg1 Type III mRNA 
Overexpression and Transcriptional Changes of 4 Genes 
from Hippocampal Microarray
Total RNA from the olfactory bulb, prefrontal cortex, dorsal 
striatum, hippocampus, and cerebellum of Nrg1 III tg and 
WT mice was assayed via standardized quantitative real-
time polymerase chain reaction procedure with TaqMan 
probes to Nrg1 III, and to targets identified by microarray 
(RIKEN cDNA 181005G02, potassium inwardly rectifying 
channel member 13, and transthyretin). mRNA expression 
was normalized to the geometric mean of reference genes 
(see supplementary materials for full details). Total protein 
was isolated from the prefrontal cortex and Nrg1 was quan-
tified using western blotting with an antibody specific to the 
C-terminus of the Nrg1 protein (1:300, sc-348, Santa Cruz 
Biotechnology, refer to supplementary materials for details).
Microarray
Hippocampal RNA of WT (n  =  10) and Nrg1 III tg 
(n = 8) mice (aged 39.5 [±2.5] weeks) were assessed using 
the Affymetrix GeneChip Mouse Gene 2.0 ST Array, per-
formed by The Ramaciotti Centre for Genomics as per 
the manufacturer’s instructions (for further details, see 
supplemental materials).
Behavioral Testing
Behavioral tests were performed in the following order: 
elevated plus maze (EPM; anxiety and exploration), 
social interaction (sociability), Y-maze (spatial memory), 
social preference task (social preference and recognition 
memory), prepulse inhibition (sensorimotor gating), 
fear conditioning (fear associated memory), and 15 min 
baseline open field (exploration and locomotion) with 
an additional 90-min period in open field after MK-801 
hydrogen malate (0.25 mg/kg, [injection volume of 10 ml/
kg body weight] subcutaneous injection: Sigma–Aldrich) 
challenge (behavioral sensitivity to N-methyl-D-aspartate 
[NMDA] receptor antagonism). Finally, mice under-
went a comprehensive physical exam, which screened 
for sensory, motor function, and neurological behavio-
rial deficits. The behavioral tasks and protocols used are 
described in our previous publications26–32 (for details of 
all tests, see supplementary material).
Statistical Analysis
For statistical procedures, please refer to the supplemen-
tary materials.
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Results
Nrg1 Type III mRNA and Protein Levels
We found a >5 times increase of normalized Nrg1 III 
mRNA in the olfactory bulb [t(17)  =  14.0, P  <  .0001], 
prefrontal cortex [t(17) = 34.3, P <  .0001], dorsal stria-
tum [t(17) = 6.8, P < .0001], hippocampus [t(17) = 13.0, 
P  <  .0001] and a ~30% increase in the cerebellum of 
heterozygous Nrg1 III overexpressing (Nrg1 III tg) mice 
compared with WT mice [t(16) = 3.0, P < .01] (figure 1A) 
confirming that insertion of multiple copies of the trans-
gene lead to robust forebrain Nrg1 type III overexpres-
sion. Supporting this, relative levels of full-length and 
cleaved Nrg1 protein from the prefrontal cortex across 
Fig. 1. Nrg1 type III mRNA and protein levels, hippocampal microarray, and validating qPCR in WT and Nrg1 III transgenic mice. (A) 
Normalized relative levels of Nrg1 type III mRNA expression in the olfactory bulb, prefrontal cortex, dorsal striatum, hippocampus, and 
cerebellum, (B) representative immunoreactive bands for Nrg1 protein with interpolated approximate band sizes, (C) normalized levels 
of Nrg1 protein levels in the prefrontal cortex, (D) normalized Nrg1 type III mRNA levels in the prefrontal cortex and hippocampus of 
postnatal day 28–29 and adult (40–42 weeks old) Nrg1 type III transgenic and WT mice, (E) volcano plot of hippocampal microarray 
with 4 representative significantly changed genes across genotype identified and (F) qPCR mRNA expression of the 3 representative 
genes. Data for control (WT) and Nrg1 type III transgenic (Nrg1 III tg) mice are shown as mean + SEM. Significant genotype effects vs 
WT are shown as “*” (*P < .05, **P < .01, and ***P < .001). Trend genotype effects vs WT is shown as “T” (T P = .053). Significant 
effect between postnatal day 28–29 and adult (40–42 weeks old) in Nrg1 III tg mice is shown as “++” (++P < .01).
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several band sizes were elevated in transgenic mice com-
pared with WT mice (126  kDa) [t(14)  =  2.4, P  <  .02], 
(82  kDa) [t(13)  =  2.6, P  <  .02], (77  kDa) [t(13)  =  1.7, 
P  =  .06], (64  kDa) [t(13)  =  3.6, P  <  .002], (54  kDa) 
[t(13)  =  1.6, P  =  .07], (44  kDa) [t(14)  =  2.4, P  <  .02], 
(40 kDa) [t(12) = 3.1, P < .004] (figures 1B and 1C).
To assess whether the transgene expression of Nrg1 
type III mRNA varies with age, Nrg1 type III mRNA 
expression levels in Nrg1 III tg and WT mice were mea-
sured at 2 time points: juvenile (postnatal day 28 [P28]) 
and adult (39.5 [±2.5] weeks) and in 2 brain regions (pre-
frontal cortex and hippocampus) (figure 1E). We found 
a significant “genotype” by “age” interaction in the pre-
frontal cortex [F(1, 25) = 11.8, P = .002] whereby Nrg1 
type III mRNA in Nrg1 III tg adult mice was significantly 
elevated compared with Nrg1 III tg P28 mice (P < .001). 
This effect was not seen in WT mice. For the hippocam-
pus, we did not detect an “age” by “genotype” interaction 
effect for Nrg1 type III mRNA levels. For both ages and 
for both regions, Nrg1 type III mRNA levels were signifi-
cantly increased in Nrg1 III tg mice compared with the 
respective age group of WT mice (P < .0001).
Hippocampal Microarray mRNA Assay Results and 
Confirmation via quantitative polymerase chain reaction
A total of 187 differentially expressed transcripts were 
detected in Nrg1 III tg mice compared with WT (figure 
1D and supplementary materials). Of the 187 transcripts, 
we selected 3 (2 of those most differentially expressed 
and 1 at moderate level of significance) and assessed 
the mRNA expression of these transcripts via qPCR in 
order to verify the results and robustness of the micro-
array analysis: RIKEN cDNA 181005G02 (upregulated 
compared with WT) [t(15) = 16.9, P < .0001], Potassium 
inwardly rectifying channel, subfamily J member 13 (down-
regulated compared with WT) [t(16) = 2.7, P = .02] and 
Transthyretin (trend downregulated compared with WT) 
[t(17) = 2.1, P = .053] (figure 1F). After validating the 
microarray, we performed a PubMed literature search 
on the 187 differentially expressed transcripts and found 
several downregulated genes that have been implicated 
in schizophrenia, including 5-hydroxytryptamine (sero-
tonin) receptor 2C,33 angiotensin converting enzyme,34 sul-
fatase 1,35 and transthyretin.36 Additionally, we screened 
for immunologically associated transcripts as Nrg1 has 
been shown to regulate the immune response in the brain37 
and abnormal neuroinflammatory processes have been 
linked to schizophrenia.38,39 In total, we found several 
altered immune-related transcripts including Serpinb1b, 
Mcfd2, Fgl2, Cldn9, Gas6, Prlr, Gulp1, Cdk6, Spint2, Lbp, 
Ltc4s, Mir9-1, Sulf1, Ifi27, Kl, Ddr2, Trpm3, Bcl2a1a, 
C1qtnf5, Cldn2, F5, Lepr, Psmb5-ps, Ucp2, Slc39a4, and 
1500015O10Rik (Ecrg4). Finally, several members of the 
insulin-like growth factor (Igf) pathway including Igf2, 
Igf binding protein 2 (Igfbp2), and Igfbp7 appear to be 
downregulated in Nrg1 III tg mice. These transcripts may 
be of interest as Igf signaling, like Nrg1 signaling, medi-
ates neurogenesis and cell survival.40
Physical Exam and General EPM Behavior
Nrg 1 III tg mice did not display deficits in motor func-
tions, neurological behaviors or in any of the sensory 
abilities measured in this test compared with WT mice (all 
Ps > .05; table 1). Using one-way ANOVA, no differences 
between Nrg1 III tg and WT mice were observed for mea-
sures of time spent in open arms, percentage of open arm 
entries, overall distance travelled in the arms of the maze 
nor for duration or frequency of grooming, head-dipping, 
rearing, and stretch-attend posture (all Ps > .05; table 1).
Social Behaviors
No differences were detected in the social interaction 
test between Nrg1 III tg and WT mice for duration and 
frequency of social behaviors or for overall active social 
interaction time (all Ps > .05; table 1). When analyzing 
the sociability trial of the social preference test, we found 
that both WT and Nrg1 III tg mice spent more time in 
the chamber containing a mouse than the empty cham-
ber [“chamber” F(1, 18) = 9.3, P = .007; no “chamber” 
by “genotype” interaction] (figure 2A) indicating normal 
preference for social stimuli, supporting our findings in 
the social interaction test. However, in the social recog-
nition/preference memory test, we found a significant 
“chamber” by “genotype” interaction effect [F(1, 18) = 
4.7, P = .04] where WT mice spent a significantly higher 
percentage of time in the chamber containing the novel 
mouse as compared with the familiar mouse [P = .03] 
whereas the Nrg1 III tg mice did not demonstrate this 
preference for the novel mouse [P = .5]. In agreement 
with this, WT mice spent a significantly higher percentage 
of time in the chamber containing the novel mouse than 
by chance [58.97%, t(18) = 2.2, P = .04], whilst the time 
spent by Nrg1 III tg mice in the chamber containing the 
novel mouse was lower and was not significantly different 
than chance [47.20%, t(18) = .8, P = .44].
Cognitive Behaviors
For the Y-maze, we did not detect a “genotype” effect 
on percentage distance travelled in the novel arm, which 
was above chance (33%) for both genotypes [t-test: WT: 
42.3%, t(18) = 5.0, P < .0001; Nrg1 III tg: 41.4%, t(18) 
= 4.2, P < .0001; and both genotypes performed simi-
larly for percentage novel arm entries and for time spent 
in novel arm: table 1]. For fear-associated learning, Nrg1 
III tg mice had WT levels of baseline freezing in the first 
2 min of the conditioning trial [F(1, 17) = 0.4, P = .5] and 
in the first 2 min of the cue trial, prior to cue presenta-
tion [F(1, 17) = 1.2, P = .3]. In contrast, Nrg1 III tg mice 
displayed reduced freezing levels compared with WT mice 
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during the first 2 min of the context trial [F(1, 17) = 6.4, 
P = .02] (figure 3A). Additionally, Nrg1 III tg mice exhib-
ited an overall reduction in total time spent freezing to the 
context compared with WT mice [F(1, 17) = 4.7, P < .05] 
indicating a deficit in contextual fear conditioning (figure 
3B). In the cue test, there was no difference in total freez-
ing duration between genotypes during cue presentation 
[F(1, 15) = 1.8, P = .2]. There was a significant “geno-
type” by “time” interaction across 1 min blocks during 
cue presentation [F(4, 15) = 3.4, P = .02]; however, we 
did not find any significant differences across genotype at 
individual time-points by post hoc analysis (figure 3C). 
Furthermore, freezing duration prior to cue presentation 
(ie, first 2 min) and during cue presentation (ie, third to 
seventh min) was not different between Nrg1 III tg mice 
and WT.
Prepulse Inhibition
For PPI testing, we found that all mice exhibited an 
increasing startle response to increasing startle stim-
uli [F(1, 18) = 40.6, P < .001; “startle” by “genotype”: 
Table 1. Results for Behavioral Measures from the Elevated Plus Maze (EPM), Social Interaction Test (SI), Y-Maze (YM), Open Field 
(OF), Prepulse Inhibition (PPI), Accelerod, and Beam Walking Task
Behavioral Test Parameter WT Nrg1 III tg F (df) Sig.
EPM Time in open arms [s] 9.4 ± 6.9 20.8 ± 6.2 1.5 (1, 18) P = .2
Time in open arms [%] 4.2 ± 3.2 9.4 ± 2.9 1.5 (1, 18) P = .2
Overall distance travelled [m] (meters) 10.5 ± 0.8 10.4 ± 0.9 0.002 (1, 18) P = 1
Stretch-attend posture [n] 27.3 ± 2.3 23.7 ± 2.2 1.3 (1, 19) P = .3
Stretch-attend posture [s] (seconds) 34.6 ± 3.3 28.9 ± 3.0 1.6 (1, 18) P = .2
Head-dipping [n] 17.2 ± 2.4 14.3 ± 2.4 0.8 (1, 18) P = .4
Head-dipping [s] 12.3 ± 1.7 10.3 ± 1.6 0.7 (1, 18) P = .4
Rearing [n] 13.5 ± 2.5 14.8 ± 2.4 0.1 (1, 18) P = .7
Rearing [s] 9.3 ± 1.7 10.9 ± 1.7 0.4 (1, 18) P = .5
Grooming [n] 8.2 ± 1.3 7.2 ± 1.2 0.3 (1, 18) P = .6
Grooming [s] 17.2 ± 2.9 12.0 ± 2.8 1.7 (1, 18) P = .2
SI Total social interaction time [s] 83.7 ± 10.3 87.3 ± 10.8 0.1 (1, 19) P = .8
Nosing/sniffing [n] 55.6 ± 3.8  57.5 ± 4.0 0.1 (1, 19) P = .7
Nosing/sniffing [s] 54.7 ± 7.4 58.7 ± 7.8 0.1 (1, 19) P = .7
Anogenital sniffing [n] 19.6 ± 2.7 19.3 ± 2.8 0.01 (1, 19) P = .9
Anogenital sniffing [s] 17.5 ± 2.5 18.4 ± 2.6 0.1 (1, 19) P = .8
Crawling over [n] 9.1 ± 1.4 8.2 ± 1.4 0.2 (1, 18) P = .6
Crawling over [s] 8.1 ± 1.8 6.2 ± 1.9 0.5 (1, 19) P = .5
Following [n] 4.3 ± 1.1 5.2 ± 1.2 0.4 (1, 19) P = .6
Following [s] 3.4 ± 0.8 3.0 ± 0.9 0.1 (1, 18) P = .7
YM Time in novel arm [%] 32.1 ± 7.7 35.3 ± 6.2 1.0 (1, 18) P = .3
Distance in novel arm [%] 42.3 ± 5.0 41.4 ± 5.2 0.1 (1, 18) P = .7
Time in entries in novel arm [%] 37.3 ± 5.2 39.7 ± 4.8 1.2 (1, 18) P = .3
OF Distance travelled at baseline [cm] 1678.9 ± 503.1 1758.0 ± 258.9 0.2 (1, 19) P = .7
PPI Overall average PPI [%] 50.0 ± 4.4 32.6 ± 4.4 5.3 (1, 18) P = .03
Accelerod Latency to fall [s] 158.7 ± 48.3 199.4 ± 60.4 2.7 (1, 16) P = .1
Beam walking task Latency to reach platform [s] 40.2 ± 25.1 26.4 ± 17.9 1.6 (1, 16) P = .2
Fig. 2. Social preference testing. (A) Sociability (ie, preference for spending time in social chamber/empty chamber) (%) and (B) social 
recognition memory (ie, preference for spending time with a novel mouse/familiar mouse) (%), where significant genotype effects vs WT 
results are shown as “*” (*P < .04), while “#” above line indicates “chamber” by “genotype” interaction (*P < .04). Data for control 
(WT) and Nrg1 type III transgenic (Nrg1 III tg) mice are shown as mean + SEM.
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F(2, 18) = 0.8, P = .4] and increased PPI with increas-
ing prepulse intensities [F(1, 18) = 75.4, P < .001] (figure 
3D). A PPI deficit was detected as the %PPI of Nrg1 III 
tg mice was significantly reduced at prepulse intensities 
of 74 [F(1, 18) = 5, P = .04] and 86 dB [F(1, 18) = 7.6, 
P = .01], but not at 82 dB [F(1, 18) = 1.7, P = .2] (figure 
3D). In line with this finding, Nrg1 III tg mice exhibited 
significantly lower PPI averaged across prepulse inten-
sities compared with WT mice [F(1, 18) = 5.3, P = .03] 
(table 1). We also assessed whether the level of Nrg1 type 
III mRNA overexpression negatively correlated with PPI 
performance by correlating Nrg1 type III mRNA levels 
in the prefrontal cortex of behaviorally tested Nrg1 III tg 
and WT mice with their %PPI. We found that increasing 
Fig. 3. Fear-associated memory, sensorimotor gating (ie, prepulse inhibition) and correlation analysis: Nrg1 type III mRNA levels with 
percentage prepulse inhibition. (A) Time spent freezing (s) in the first 2 min of conditioning trial, context trial and cue trial, (B) total 
freezing time (s) during context test, (C) time spent freezing (s) during cue trial, shown in 1-min blocks, (D) percent prepulse inhibition 
(%) at 3 different prepulse intensities, and (E) inverse correlation of prefrontal cortex Nrg1 type III expression with percentage prepulse 
inhibition performance (r = Pearson’s correlation co-efficient). Significant genotype effects vs WT results are shown as “*” and “**” (*P 
< .05, **P < .001), while “#” above line indicates “time” by “genotype” interaction (*P < .05). Data for control (WT) and Nrg1 type III 
transgenic (Nrg1 III tg) mice are shown as mean + SEM.
Downloaded from https://academic.oup.com/schizophreniabulletin/article-abstract/doi/10.1093/schbul/sbx122/4107794/Overexpression-of-Neuregulin-1-Type-III-Confers
by University of Tasmania Library user
on 20 October 2017
Page 7 of 11
Transgenic Mouse Model for Nrg1 Type III
Nrg1 type III mRNA levels correlated with impaired PPI 
performance [r = −.53, P = .03] (figure 3E).
Baseline and MK-801-Induced Open Field Behavior
We detected a significant effect of  “time” for distance 
travelled during the first 15 min of  the open field test 
indicating intact habituation [F(14, 16) = 3.3, P = .007]; 
however, we did not detect a significant “time” by “gen-
otype” interaction effect (figure 4). Furthermore, over-
all baseline locomotion during these 15 min was almost 
identical between genotypes [F(1, 19) = .2, P >.7] (table 
1). Comparing baseline locomotion to the first 15 min 
following drug treatment showed a significant effect 
of  “time” for total distance travelled [F(1, 16) = 29.2, 
P < .001], while no “time” by “genotype” interaction 
was found [F(1, 16) = .1, P = .7]. Locomotion post drug 
treatment across 5-min blocks was increased as a result 
of  the MK-801 treatment [RM ANOVA for “drug”: 
F(1, 17) = 37.6, P < .001]; however, no “genotype” or 
“drug” by “genotype” interaction effect was detected 
(figure 4B).
Discussion
Here, we created a transgenic mouse that mimics the 
overexpression of Nrg1 type III in the brain that is linked 
to increased genetic risk of developing schizophrenia. We 
find that this mouse can serve as a model of aspects of 
schizophrenia-like behavior (ie, endophenotypes) as defi-
cits in social recognition memory, contextual fear condi-
tioning, and sensorimotor gating were detected. However, 
more general social behaviors, baseline locomotion and 
exploration, locomotor response to MK-801, and anxi-
ety did not appear to be altered. Additionally, we have 
uncovered schizophrenia-related transcriptional changes 
in the hippocampus of Nrg1 III tg mice.
Nrg1 III tg mice did not possess sensory, neurological 
reflex, or motor deficits in the domains measured; nor do 
they have a generalized anxiety phenotype. This suggests 
that effects of Nrg1 III overexpression on schizophrenia-
like behavior is a consequence of impaired higher order 
processing of information, and not of an underlying phys-
ical impairment or stress response-related differences.
Assessing social interaction in our mice was of inter-
est as schizophrenia patients have difficulty in forming 
and maintaining meaningful social relationships.41 We 
found that Nrg1 III tg mice preferred the presence of 
another mouse over an empty chamber. However, Nrg1 
III tg mice failed to exhibit a normal preference toward a 
novel mouse, suggesting that an overexpression of Nrg1 
type III might contribute toward an aversion or lack of 
preference toward social novelty. Similarly, Nrg1 trans-
membrane domain heterozygous mice have normal levels 
of sociability in social preference task but have reduced 
social preference for the novel mouse.42 Two separate 
mouse lines with CamKIIα promoter driven overproduc-
tion of Nrg1 type I exhibit both social withdrawal and a 
loss of preference for the novel mouse.21,43 These results, 
in tandem with ours, highlight the importance of isoform 
specific levels of Nrg1 in relation to each other in mediat-
ing social deficits that may resemble the negative symp-
toms of schizophrenia.
Cognitive symptoms in schizophrenia patients cor-
relate with structural and functional abnormalities in 
brain regions including the hippocampus (HPC).44 Fear 
conditioning in rodents requires highly integrated brain 
circuitry which includes the HPC.45 We found impover-
ished fear-associated memory to context in the Nrg1 III 
tg mouse, a result which occurs across numerous other 
Nrg1 perturbations.25,43,46,47 We found alterations in the 
hippocampal transcriptome of Nrg1 III tg mice that may 
provide clues in uncovering the mechanisms behind this 
behavioral phenotype. One downregulated transcript 
Fig. 4. Baseline and MK-801 induced locomotion in the open 
field test. (A) Distance travelled (cm) across 1-min blocks in 
the first 15 min (drug-free) and (B) distance travelled (cm) 
across 5-min blocks during the 105-min test period. A single, 
intraperitoneal injection (IP) of 0.25 mg/kg of MK-801 was given 
after 15 min of baseline testing. Data are shown for control (WT) 
Nrg1 type III transgenic (Nrg1 III tg) and mice are presented as 
mean + SEM.
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relating to the serotonin pathway, 5-hydroxytryptamine 
(serotonin) receptor 2C, has been shown to be reduced in 
schizophrenia patients33 and has also been shown to mod-
ulate conditioned fear to context in rodents.48 Due to our 
findings, we intend to undertake further investigations 
into the signaling pathway of a few of these candidate 
genes and assess whether Nrg1 type III upregulation may 
disrupt these pathways in the hippocampus and cause 
deficits in fear conditioning in Nrg1 III tg mice.
In addition to altered 5-hydroxytryptamine (sero-
tonin) receptor 2C, our microarray revealed other altered 
mRNA transcripts in the hippocampus of Nrg1 III tg 
mice which bear relevance to schizophrenia including 
changes in angiotensin converting enzyme,34 sulfatase 1,35 
and transthyretin.36 Interestingly, the DiGeorge critical 
region gene 8 haploinsufficiency mouse (Dgcr8+/−) also 
shares many of the same hippocampal transcriptional 
alterations as the Nrg1 III tg mouse, suggesting that 
alterations to either Nrg1 III and Dgcr8 may impact on 
similar transcriptional processes in the hippocampus. 
The Dgcr8+/− mouse possesses compromised hippocam-
pal neurogenesis and cognitive deficits, both of which are 
reversed with the infusion of hippocampal Igf2.49 Given 
the similarity in the hippocampal transcriptomic profile 
between the Dgcr8+/− and Nrg1 III tg mice, and the role 
of Nrg1 in modulating hippocampal neurogenesis,50,51 
we suggest that investigating the role of Nrg1 III overex-
pression in neurogenic regions in the Nrg1 III tg mouse, 
and whether any abnormality in this domain implicates 
altered Igf signaling will be of interest for further studies.
Interestingly, we also found alterations in 26 immu-
nologically associated transcripts in the hippocampus 
of Nrg1 III tg mice. Several of these transcripts includ-
ing Fgl2, Gas6, Ltc4s, Ifi27, Kl, Cldn2, Lepr, Ucp2, and 
1500015O10Rik (Ecrg4) are of particular interest as 
they have demonstrated the capacity to modify immune 
responses within the brain or in neuronal cell culture.52–60 
Given the link between inflammation and schizophre-
nia,38,39 and also emerging evidence illustrating that Nrg1 
signaling may be able to influence the inflammatory-like 
pathways in the brain,37 it may be of value to continue to 
assess the role of Nrg 1 type III overexpression on brain 
inflammation within the context of schizophrenia-like 
neuropathology.
PPI is commonly impaired in schizophrenia patients61 
and the measurement of  PPI in humans and mice is 
almost identical.30 We found that male Nrg1 III tg mice 
exhibited a PPI deficit which is comparable to the PPI 
deficit found in Nrg1 type III haploinsufficient mice,19 
whereas a complete knockout of  Nrg1 III postnatally 
does not induce a PPI deficit.25 Additionally, we found 
that increasing Nrg1 type III mRNA levels predicted 
worse PPI performance. Thus, the type of  Nrg1 isoform, 
magnitude of  expression, location of  transgene expres-
sion and timing of  isoform change may mediate changes 
in sensorimotor gating. If  normal adult PPI performance 
is contingent on the timing of  the expression of  certain 
Nrg1 isoforms and optimal levels of  Nrg1, assessing 
Nrg1 III overexpression within the context of  pre and 
perinatal development might provide insight into the 
neurobiological development of  this schizophrenia-like 
behavioral phenotype. Our result supports that, in our 
transgenic mice, the impact of  overexpression of  Nrg1 
type III could be mediated before adulthood when PPI 
was assessed, as we found increased expression of  Nrg1 
III mRNA in the juvenile brain prior to adolescence.
The overall conditioned fear response to a discreet cue 
in the Nrg1 III tg mouse was at the level of WT mice. The 
subtle “genotype” by “time” interaction during cue pre-
sentation suggests that fear response to the conditioned 
cue over an extended period of exposure may be altered 
and future work on the extinction of a learned fear might 
be warranted. At present, only one study has assessed 
the role Nrg1 on extinction fear memory, wherein hypo-
morphic Nrg1 II rats froze less during extinction trials to 
a discreet cue 96 h after conditioning.62 Similarly to our 
finding, both full-length and N-terminal fragment over-
expression of Nrg1 does not appear to elicit a deficit in 
learned fear to cue,20,43 suggesting that an upregulation of 
Nrg1 may not play a role in disrupting basic learned fear 
to a discreet cue.
Our results suggest that short-term spatial memory 
is intact with forebrain Nrg1 type III overexpression as 
Nrg1 III tg mice exhibited WT levels of exploration of 
the novel arm on the Y-maze. Other Nrg1 mouse mod-
els, however, exhibit impairments in short-term/work-
ing spatial memory in a variety of cognitive tasks. The 
heterozygous Nrg1 type III knockout mouse has deficits 
in 60 s delayed spontaneous alternation19 while an Nrg1 
type I overexpressing mouse has decreased performance 
in several spatial memory tasks, which is rescued when 
transgene expression is shut-off  in adulthood.21 Together, 
these results suggest that short-term spatial memory def-
icits in Nrg1 mutant mice might be isoform dependent 
and/or vulnerable to changes in the specific concentration 
of these Nrg1 isoforms relative to one another.
Our Nrg1 III tg mouse failed to have the expected base-
line or drug-induced increases in locomotion. Baseline 
ambulatory distance travelled in an open field arena did 
not appear to be impacted by Nrg1 type III overexpres-
sion. This is in alignment with the heterozygous Nrg1 type 
III knockout mouse that also does not exhibit hyperloco-
motion.19 Furthermore, several other Nrg1 I overexpress-
ing mice only show a locomotor phenotype under certain 
conditions (eg, dependent on age or drug treatment).22,63 
We did not observe a genotype difference in mice exposed 
to MK-801, suggesting that Nrg1 type III overexpression 
does not alter the response to NMDA receptor perturba-
tion known to induce hyper-locomotion.
Our study possesses limitations, including the use of 
only male mice. It is important to interrogate the molec-
ular and behavioral phenotypes in both male and female 
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mice in order to assess how abnormal Nrg1 signaling 
may be contributing to the schizophrenia-like symptoms 
in both males and females. Thus, using the effect sizes 
from this study, we intend to follow-up with comprehen-
sive characterization of  female Nrg1 III tg mice. Another 
limitation is that we only used one transgenic line and 
thus cannot rule out the impact of  transgene insertion 
on the phenotypes observed in the Nrg1 III tg mouse. 
Additionally, the overexpression of  forebrain Nrg1 type 
III mRNA in Nrg1 III tg mice was >5 times higher than 
WT mice while schizophrenia patients carrying NRG1 
HapICE alleles only have a ~30% elevation in Nrg1 type 
III mRNA compared with non NRG1 HapICE allele car-
riers.6 However, it is worth mentioning that several Nrg1 
type I transgenic mouse models also overexpress Nrg1 
by a magnitude of  >4 times.20,21,23,43 Another limitation 
of  the study is that we did not assess whether antipsy-
chotics are capable of  reversing the schizophrenia-like 
behavioral deficits exhibited by Nrg1 III tg mice (ie, test 
predictive validity of  model). Future studies may con-
sider including an antipsychotic treatment in this trans-
genic mouse model.
In sum, the results of this study indicate that forebrain 
driven overexpression of Nrg1 III in a novel mouse model 
causes schizophrenia-like deficits across several behavioral 
domains and supports the candidacy of this transgenic 
mouse model for future studies. Given that a subset of 
schizophrenia patients carry copies of the NRG1 HapICE 
gene, which appears to upregulate NRG1 III in their fore-
brain, evidence from the current study gives weight toward 
the role of forebrain NRG1 III overexpression contribut-
ing toward some of the clinical symptoms of the disease, 
at least in a subset of individuals. Additionally, these find-
ings also highlight the use of this Nrg1 III overexpressing 
model to assess the biological consequences of the upregu-
lation of this isoform type. Future research will need to 
be conducted in order to extend our understanding of 
forebrain driven Nrg1 type III overexpression on schizo-
phrenia related phenotypes. For example, it will be relevant 
to assess if NRG1 type III overexpression (eg, in PFC) is 
linked to increased ErbB4 activity. In line with our previ-
ous work, we will also consider sex effects and gene–envi-
ronment interactions in our new model.64–66
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